Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × NSCLC × aflutinib × Clear all

Phase

Phase 2 3 Phase 1 3 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Pemetrexed 2 Gefitinib 2 spartalizumab 1 aflutinib 1 Tyrosine Kinase Inhibitors 1 Thalidomide 1 Radiosurgery 1 Platinum 1 Immune Checkpoint Inhibitors 1 Drug Therapy 1 Axitinib 1 Aspirin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05209256 2022-01-26

Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC

The First Affiliated Hospital of Henan University of Science and Technology

Phase 2/3 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡